Details of the Drug
General Information of Drug (ID: DMIHO0P)
Drug Name |
PIPEROXAN
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Piperoxan; Benodaine; Piperoxane; 59-39-2; Fourneau 933; Piperoxan [INN:BAN]; Piperoxanum [INN-Latin]; Piperoxane [INN-French]; F933; Piperoxano [INN-Spanish]; 2-Piperidinomethyl-1,4-benzodioxan; 933F; Piperidine, 1-(1,4-benzodioxan-2-ylmethyl)-; BRN 0222516; CHEMBL31836; NCGC00160643-01; Piperidine,1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-; 1,4-Benzodioxane, 2-(piperidinomethyl)-; Piperidine, 1-((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-; 1,4-BENZODIOXAN, 2-(PIPERIDINOMETHYL)-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 233.31 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||